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Transfusion-Related Acute Lung Injury: What the Allied Health Professional Needs to Know about this
Life -Threatening Hazard of Blood Transfusion
Transfusion-Related Acute Lung Injury (TRALI) is a rare, life-threatening hazard of blood transfusion. In the
intensive care unit, 37% to 44% of admitted patients are transfused with at least one blood component. The
opportunity for health professionals and students from nursing, respiratory care, and clinical laboratory
science to interact directly with patients receiving a blood transfusion is likely to present itself on a daily basis.
It is imperative for those caring for critically ill patients to be fully aware of the clinical signs of TRALI and
have knowledge in the prevention and treatment of this clinical syndrome. Common clinical signs of TRALI
include cough, fever, and dyspnea. Treatment has been mostly supportive and aimed at reversing acute
respiratory distress through oxygen therapy or mechanical ventilation. In 2004, a consensus panel and the U.S.
National Heart, Lung, and Blood Institute (NHLBI) working group characterized TRALI as new-onset acute
lung injury (ALI) occurring within six hours of transfusion in patients without preexisting ALI. Although the
condition is uncommon, knowledge of this clinical syndrome may help identify those patients at risk and may
prevent lung injury and possible death due to this rarely encountered hazard of blood transfusion.
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ABSTRACT 
Transfusion-Related Acute Lung Injury (TRALI) is a rare, life-threatening hazard of blood transfusion. In the intensive care unit, 
37% to 44% of admitted patients are transfused with at least one blood component. The opportunity for health professionals and 
students from nursing, respiratory care, and clinical laboratory science to interact directly with patients receiving a blood 
transfusion is likely to present itself on a daily basis. It is imperative for those caring for critically ill patients to be fully aware of 
the clinical signs of TRALI and have knowledge in the prevention and treatment of this clinical syndrome. Common clinical signs 
of TRALI include cough, fever, and dyspnea. Treatment has been mostly supportive and aimed at reversing acute respiratory 
distress through oxygen therapy or mechanical ventilation. In 2004, a consensus panel and the U.S. National Heart, Lung, and 
Blood Institute (NHLBI) working group characterized TRALI as new-onset acute lung injury (ALI) occurring within six hours of 
transfusion in patients without preexisting ALI. Although the condition is uncommon, knowledge of this clinical syndrome may 
help identify those patients at risk and may prevent lung injury and possible death due to this rarely encountered hazard of blood 
transfusion.  
 
INTRODUCTION 
In the acute care hospital, blood transfusions are utilized by physicians on a daily basis.1 Transfusion of whole blood or one of 
the components of blood is usually completed in an uneventful manner; however, some recipients may experience complications 
that range from mild to life threatening, including severe hypoxemia, bilateral pulmonary edema, and allergic reactions.2 For 
health professionals and students caring for critically ill patients, it is important to be fully aware of the hazards of blood 
transfusion. In the intensive care unit (ICU), 37 to 44% of admitted patients are transfused with at least one blood component.3 
The opportunity to interact directly with patients receiving a blood transfusion in the ICU is likely to present itself to health 
professionals and students from nursing, respiratory care, and clinical laboratory science. This article will examine transfusion-
related acute lung injury (TRALI); a life-threatening complication of blood transfusion.4 Included in this discussion will be the 
incidence, definition, pathophysiology, prevention, and treatment of TRALI.  
  
INCIDENCE  
TRALI represents a leading cause of transfusion-related deaths.5,6 In the United States, between 2003 and 2005, there were 550 
reported cases of TRALI, but it is suspected that there may be many more cases that were not reported.7,8 Incidence is difficult to 
estimate because there are no published large clinical trials of TRALI. However, estimates range from 1 in 300 to 1 in 5000 
transfusions.9 The incidence of TRALI is the same for males and females, and it has been known to occur in patients of all 
ages.10,11 A correct diagnosis of TRALI can be difficult because of a variety of pulmonary complications and other types of 
transfusion reactions that may easily interfere with the diagnosis. An incidence of acute lung injury (ALI) may not readily be 
associated with the transfusion of plasma or other blood products the patient may be receiving as the etiology of TRALI is 
complex and is not always clear-cut.  
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DEFINITION 
TRALI is defined as a clinical syndrome, not a disease arising from a single cause.12 The difficulty in diagnosing TRALI is a result 
of the lack of a “gold standard” diagnostic tool.1 Therefore, a diagnosis relies on the assessment of clinical symptoms (e.g., 
dyspnea, cough, fever) and the exclusion of other transfusion reactions.13 In diagnosing TRALI, the healthcare practitioner 
should exclude the most common reason for pulmonary edema and subsequent respiratory distress in a patient receiving a 
blood transfusion, transfusion-associated circulatory overload (TACO). TACO is important to rule out because it can mimic 
TRALI as both are associated with pulmonary edema.2 Another reason TRALI may be difficult to diagnose is the complex picture 
presented by overlying disease processes (e.g., pneumonia, severe sepsis, shock) that may be occurring at the same time.12 A 
consensus panel and the U.S. National Heart, Lung, and Blood Institute (NHLBI) working group convened in 2004 to develop a 
clinical definition for this syndrome. The definition is based on clinical and radiological parameters developed by the consensus 
panel and are presented in table 1.1 
 
 
Table 1: Definition of TRALI1 
Suspected TRALI 
Acute onset within 6 hours of blood transfusion 
Bilateral infiltrates changes on chest radiograph 
       PaO2/FIO2 ≤300 mmHg, or worsening of P to F ratio 
No sign of hydrostatic pulmonary edema (PAOP ≤ 18 mmHg or central venous 
pressure ≤ 15 mmHg) 
No other risk factor for acute lung injury 
Possible TRALI 
Same as for suspected TRALI, but another risk factor present for ALI 
Delayed TRALI 
      Same as for (possible) TRALI and onset within 6-72 hours of blood transfusion 
 
ALI = acute lung injury; FIO2 = fraction of inspired oxygen; PaO2 = arterial oxygen, PAOP = pulmonary artery 
occlusion pressure; TRALI = transfusion-related acute lung injury. 
 
 
The consensus panel characterized this syndrome as new-onset acute lung injury occurring within six hours of transfusion in 
patients without preexisting ALI.1 ALI is defined by the North American European Consensus as new-onset hypoxemia with 
bilateral pulmonary infiltrates occurring on the chest radiograph in the absence of volume overload and a blood oxygen 
saturation of 90% or less on room air.14 Due to the lack of specific diagnostic markers, the consensus panel recommends utilizing 
the definition in Table 1 for clinical practice and research.15 
 
PATHOPHYSIOLOGY 
A diagnosis of TRALI is strongly supported after finding anti-HLA antibodies (antibodies to human leukocyte antigens) or other 
anti-leukocyte antibodies in the donor’s plasma.16 It is currently believed that one cause of TRALI is the transfer of anti-human 
leukocyte antibodies from the donor to the recipient that may cause primed leukocytes in the recipient’s lungs to de-granulate, 
setting up an acute inflammatory response in the lung parenchyma. The resulting capillary leakage is likely the inflammatory 
process that causes the associated pulmonary edema.17 This hypothesis is supported by look-back studies that show that most 
cases of TRALI are associated with transfusions of plasma or other components that contain plasma.9 To further support the 
donor antibody hypothesis, it has been noted that plasma products from female multiparous donors, or women that have had two 
or more pregnancies, pose a greater risk for TRALI than products from male donors.18 This suggests that female multiparous 
donors that have been repeatedly exposed to fetal HLA antigens may generate a wide variety of HLA antibodies or anti-
neutrophil antibodies. Theoretically, plasma from male donors would contain very little, if any, of these types of antibodies unless 
the donor had previously received multiple blood transfusions. In 2003, the United Kingdom blood system recommended 
eliminating from inventory the fresh frozen plasma of female donors.19 Donor centers in the United States soon followed, 
preferring male only donors for the production of plasma products.20  
 
There is also evidence to suggest that TRALI may have another cause. In some cases of TRALI, there have been no antibodies 
associated with this condition. Investigation in this area has created an interesting hypothesis called the “two hit” theory. In this 
model, the first “hit” is a predisposing factor that causes circulating leukocytes to adhere to the capillary endothelium in the 
alveoli. This insult can be caused by pneumonia, surgery, trauma, near drowning, or massive transfusion. The pulmonary 
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leukocytes are then stimulated by the second “hit” of priming molecules causing the sequestered leukocytes to release oxidases 
and proteases with resulting damage to the capillary endothelium. It is this immunological damage that causes leakage of fluid 
into the air spaces.5  
 
These priming molecules called the “second hit” are contained in the transfusion. Priming lipids are biological response modifiers 
that can bind to receptors on sequestered leukocytes and initiate degranulation. It has been demonstrated that soluble CD40 
molecules may also be responsible for the second hit that initiates leukocyte activation. Components containing red blood cells 
shed larger amounts of these types of molecules into the plasma.21 These molecules are believed to be breakdown products 
released from platelets and red blood cell membranes in the component bag. 
 
Biological response modifiers tend to accumulate over time in stored blood components. The length of storage time is directly 
related to the amount of these molecules that are present in the plasma fraction of the component. One study has demonstrated 
that red cells stored for as little as 15 days under recommended storage conditions could produce enough priming molecules to 
activate neutrophils, while red cells stored for 35 days showed the greatest propensity for stimulating neutrophils.22 Animal 
studies have also supported the two hit hypothesis. Lungs of rats were pretreated with lipopolysaccharide endotoxin to adhere 
neutrophils to the capillary endothelium. Plasma from fresh blood and from blood stored at 42 days (the normal outdate period 
for red blood cells) was then perfused into the pretreated lungs and the rats were monitored for acute lung injury. Rat lungs 
perfused with plasma from a freshly drawn blood unit did not demonstrate ALI while rat lungs perfused with plasma extracted 
from 42 day-old red blood cells showed significant pulmonary edema.23  
 
TREATMENT  
The treatment of TRALI is mostly supportive and aimed at reversing acute respiratory distress through oxygen therapy, 
noninvasive positive pressure ventilation by mask, (e.g., continuous positive airways pressure), or mechanical ventilation. In 70 
to 90% of cases, patients require endotracheal intubation with subsequent mechanical ventilation. TRALI is categorized as a 
form of acute lung injury thereby utilizing a lung-protective strategy with low tidal volumes (6 to 8 ml/kg predicted body weight) is 
recommended.1 Mechanical ventilation (MV) can be a lifesaving intervention; however, one source reveals that MV may induce 
or aggravate lung injury known as ventilator induced lung injury (VILI).23 It has been reported in one study that up to 33% of 
mechanically ventilated critically ill patients developed lung injury within 48-hours of transfusion.4, 24 Vlaar et al reported in an 
animal study that MV may prime pulmonary neutrophils, putting the lungs at risk for a TRALI reaction.4  
 
In a case report by Huang et al, the authors reported a patient with severe TRALI who, failing conventional mechanical 
ventilation, was successfully transferred to High-Frequency Oscillatory Ventilation (HFOV) for rescue from refractory 
hypoxemia.25 Huang et al showed HFOV was effective in correcting refractory hypoxemia in two days and the patient was 
transferred back to conventional mechanical ventilation with ventilator liberation in two weeks. 25 The authors suggest HFOV may 
be considered as a rescue therapy for severe TRALI patients not responding to conventional mechanical ventilation. Other 
strategies that have proven to enhance improvements in oxygenation in patients with TRALI include prone position, nitric oxide 
inhalation, and extracorporeal membrane oxygenation.25 Pharmacologic therapy used to treat TRALI includes systemic 
corticosteroids, diuretics, and pressors. Use of systemic corticosteroids to reduce inflammation in the lungs does not have 
supporting evidence to prove benefits or effectiveness.26 The inhaled corticosteroid budesonide is being studied as a 
preventative strategy in a multicenter evaluation as a nebulized solution used for patients at high risk for ALI.27 Diuretics may 
show promise in maintaining a restrictive fluid strategy that is beneficial in ALI; however, another source states the use of 
diuretics to treat TRALI may be harmful, resulting in decreased cardiac output and may contribute to hypotension.1,2 For those 
patients with prolonged hypotension, the use of pressor agents may be required to maintain blood pressure.2 
 
PREVENTION 
Patients with previous lung injury may be predisposed to develop TRALI if they receive a transfusion of plasma containing 
products, whole blood, or even packed red blood cells.9 It would be prudent to be conservative in the transfusion of blood or 
plasma to these patients. If transfusion is absolutely necessary, plasma from male donors is always the first choice, and in fact, 
most donor centers do not process plasma from multiparous female donors.20 If red cells are needed to boost oxygen carrying 
capacity, fresh red blood cells should be transfused, as it has been shown that fresher units contain smaller amounts of 
neutrophil priming lipids.22 Fresh red blood cells should be requested from the blood bank, so the laboratory must be made 
aware of the risk to the patient. 
It would seem that one central issue in the prevention and treatment of TRALI is medical education. Recognition and treatment of 
TRALI crosses several disciplines: nursing, respiratory care, and the clinical laboratory. Nursing personnel are the front line care-
givers and must be able to quickly identify the signs and symptoms of ALI associated with transfusion. The respiratory care 
practitioner must be made aware of those patients receiving a blood transfusion in order to be prepared to administer the 
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appropriate therapy including monitoring the oxygenation and ventilation status of the patient. The blood bank in the clinical 
laboratory should be alerted to utilize the freshest blood to be cross-matched for patients with high risk factors for TRALI. It is 
imperative that every department involved understands the signs, symptoms, and pathology associated with TRALI and 
effectively communicates with each other. The standard of care would include informing the attending physician of any signs or 
symptoms of ALI associated with transfusion. 
 
CONCLUSION 
As patient advocates, health professionals should have knowledge of the clinical signs of TRALI, be able to recognize the 
condition, and must report any unusual reactions for patients receiving a blood transfusion to the attending physician. In an effort 
to increase awareness of TRALI, the educational curricula for nursing, respiratory care, and clinical laboratory science should 
include an instructional module on the etiology, prevention, and treatment of this clinical syndrome. Although the condition is 
uncommon, knowledge of TRALI may help identify those patients at risk and may prevent lung injury and possible death as a 
result of this rarely encountered hazard of blood transfusion.  
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